Dr. Katherine Gordon
Katie Gordon serves as Chief Business Officer of Metro Biotech. Prior to joining Metro in April 2020, she was a business consultant for venture capital – backed startup companies and investment groups, on business strategies, alliances, and diligence on emerging investments. From 2009 – 2017, Katie led Brown University’s Technology Ventures Office as Managing Director, developing partnerships with industry for commercialization of Brown and affiliated hospitals’ research discoveries. Previously, she was Director of Business Development at Harvard’s Office of Technology Development, negotiating partnerships with industry based on discoveries at Harvard. Katie previously founded and ran as CEO Apollo Biopharmaceutics, a biotech company that developed novel neuroprotective products for the treatment of Alzheimer’s disease (acquired by MitoKor). Earlier in her career, Katie was Associate Director at Integrated Genetics and Genzyme, where she was the co-inventor of technology to produce pharmaceutical proteins in animal milk, a discovery that led to an approved novel pharmaceutical product.
Dr. Gordon has a PhD in Molecular Biology from Wesleyan University and a BSc in Biology with a minor in Biochemistry from Simon Fraser University. She had a post-doctoral fellowship at Yale University.